Merck releases early PD-1 melanoma data

Share this article:

Merck's Phase Ib pipeline melanoma drug lambrolizumab shows that 81% of advanced melanoma patients survived for one year, across all doses. The company announced the data at the Congress of the Society for Melanoma Research in Philadelphia Monday.

The early data is a toehold of sorts in a PD-1 competition: PMLive notes that BMS has the Phase III PD-1 contender nivolumab, and Roche and  AstraZeneca also have anti-PD-1 drugs in the mix.

The class is considered a potential force across several indications, including melanoma and non-small lung cancer.

Monday's data correlates closely with Merck's increased focus on a smaller portfolio which will include vaccines, oncology, diabetes and acute care.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.